Pharmaceuticals, Biotechnology and Life Sciences
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.
UPDATE contains comment from Lilly
Eli Lilly has quit from a research and licence agreement with a Paris-listed clinical stage pharmaceutical company Adocia, the French company said on Friday.
French drugmaker Adocia, encouraged by the outcome of its project BC Lispro, has set its goal on partnering up with companies that have “more mature projects”, such is Eli Lilly with whom Adocia worked on BC Lispro.
Adocia and Eli Lilly have completed an insulin pump study under the Adocia-Lilly partnership evaluating BioChaperone Lispro, an ultra-rapid formulation…
Adocia a clinical stage biopharmaceutical company announced today third quarter revenue and net cash position ending September 30,2016.